Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 févr. 2020 16h08 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...